<DOC>
	<DOCNO>NCT00847483</DOCNO>
	<brief_summary>Compare IOP lower property latanoprost , travoprost bimatoprost</brief_summary>
	<brief_title>Comparison Latanoprost With Travoprost Bimatoprost Patients With Elevated IOP . A 12-Weeks , Masked Evaluator , Phase IV Multi-Center Study US</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Unilateral bilateral primary open angle glaucoma ( POAG ) , exfoliative glaucoma , pigmentary glaucoma ocular hypertension ( glaucoma define either visual field defect glaucomatous change optic nerve head association elevate intraocular pressure . Ocular hypertension define IOP ≥ 21 mmHg diagnosis ) . Is currently receive ( screen visit ) receive topical monotherapy dual therapy ( within past 6 month ) POAG ocular hypertension . Required washout period 4 week adrenergic antagonist , prostaglandin analogue ( include latanoprost , unoprostone , travoprost bimatoprost ) 2 week adrenergic agonist , 5 day cholinergic agonist carbonic anhydrase inhibitor , prior baseline visit . Mean 8 AM IOP ≥ 23 mmHg baseline visit patient . Patients assign treatment 8 PM IOP obtain . Visual acuity ( best correct ) equal good 20/200 ( Snellen ) . ETDRS chart may use convert Snellen unit . Informed Consent : Signed Informed Consent obtain screen visit . Able adhere treatment/visit planUnilateral bilateral primary open angle glaucoma , capsular glaucoma , pigmentary glaucoma ocular hypertension . Open angle glaucoma appear 6 month cataract surgery recognize primary open angle glaucoma . ( individual require treatment bilaterally must fulfill eligibility criterion eye . ) IOP 22mmHg high obtain prestudy period . Ocular condition Closed/barely open anterior chamber angle history acute angle closure . ( Patients diagnose POAG successful peripheral iridotomy may enrol ) . History ALT ( Argon Laser Trabeculoplasty ) within 3 month prior screen visit ( unlasered eye may enrol study eye ) . History ocular filter surgical intervention ( unfiltered eye may enrol study eye ) . Ocular surgery ( globe eye ) , inflammation/infection within 3 month prior screen visit . ( Applies fellow study eye . ) Hypersensitivity benzalkonium chloride component latanoprost ( Xalatan ) , travoprost ( Travatan ) bimatoprost ( Lumigan ) . Other abnormal ocular condition symptom prevent patient enter study , investigator 's clinical judgement . Other condition Use systemic medication know affect IOP ( i.e. , alphaadrenergic agonist , betaadrenergic antagonist , calcium channel blocker , ACE inhibitor and/or angiotensin II receptor blocker , corticosteroid ) , unless patient medication dosage stable three month prior screen visit dosage expect change study . Women Women childbearing potential ( WOCBP ) use contraceptive method . Women childbearing potential defined woman surgically sterile postmenopausal ( least 12 month without menstrual period ) . Contraception define abstinence , vasectomized partner , ongoing use approve oral , injectable implanted contraceptive , barrier method , IUD . Pregnancy . Women childbearing potential ( WOCBP ) must negative urine pregnancy test screen visit baseline visit . Nursing mother General Use investigational medication within 30 day prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>latanoprost</keyword>
	<keyword>travoprost</keyword>
	<keyword>bimatoprost</keyword>
</DOC>